Miguel ForteChief Executive Officer at Bone Therapeutics
Miguel Forte is CEO of Bone Therapeutics, where he is currently leading the company in its transformation to a prominent position developing engineered MSC derived cell and gene therapy for multiple indications. Miguel is also part of the Board of Directors for the Alliance for Regenerative Medicine and Essenscia-Wallonie. He is additionally visiting Professor at the Lisbon University in Portugal.
Before joining Bone Therapeutics in 2020, Forte was CEO of Zelluna Immunotherapy from 2017 to end of 2019, where he oversaw the evolution of the company from a start-up to a pre-clinical stage allogeneic cell therapy developer for solid tumors. Also, Forte was the Chief Commercialization Officer and Chair of the Commercialization Committee of the International Society of Cellular Therapy between 2016 and 2020. From 2010 to 2017 Forte was CMO and COO of TxCell, establishing and leading a professional translational approach in CGT product development for autoimmune diseases and transplantation.
Forte holds an M.D. from the Faculty of Medicine of the University of Lisbon, a Ph.D. in Immunology from the University of Birmingham, an accreditation as Specialist in Infectious Diseases and a certificate on Health Economics of Pharmaceuticals and Medical Technologies from the Stockholm School of Economics.